logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Harrow Acquires Santen’S Branded Ophthalmic Portfolio

Jul 18, 2023•over 2 years ago

Acquiring Company

Harrow

Acquired Company

Portfolio

NashvillePharmaceuticalBiotechnology

Description

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:

Company Information

Company

Harrow

Location

Nashville, Tennessee, United States

About

Harrow (NASDAQ: HROW) is a growing leader in the ophthalmic healthcare market, dedicated to innovation and providing affordable, accessible medications. By closely listening to the needs of providers and patients, the company delivers high-quality products and services. Harrow’s commitment to excellence has made it one of the fastest-growing ophthalmic pharmaceutical companies in the United States.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed